Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study
作者: Doriana LandiMaria AlbaneseFabio ButtariFabrizia MonteleoneLaura BoffaSilvia RossiCaterina MottaElisa PumaDiego Centonze
作者单位: 11 Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy
2 2 IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed, Pozzilli (Is), Italy
3 3 Neuroimmunology and Neuromuscular Diseases Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan, Italy
4 4 Biogen Italy, Medical Department, Milan, Italy
刊名: PLOS ONE, 2017, Vol.12 (7)
来源数据库: PLOS
DOI: 10.1371/journal.pone.0165415
原始语种摘要: Flu-like syndrome (FLS) is a common adverse event experienced by patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon beta (IFNβ). FLS can lead to poor treatment adherence and early IFNβ discontinuation. The involvement of interleukin-6 (IL-6) in the occurrence of FLS has been suggested. We hypothesized that cetirizine, a second-generation histamine H1 receptor antagonist able to reduce the levels of IL-6, might improve IFNβ-induced FLS.;;We conducted a pilot, cross-over, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine 10 mg added after each IFNβ injection to the standard of care for FLS (acetaminophen or nonsteroidal anti-inflammatory drugs) on FLS in patients with RRMS treated with IFNβ. Patients were randomized to...
全文获取路径: PLOS  (合作)
分享到:
来源刊物:
影响因子:3.73 (2012)

×
关键词翻译
关键词翻译
  • treatment 处理
  • cross-over 跨接
  • pilot 驾驶员
  • remitting 减轻
  • standard 标准
  • interferon 干扰素
  • placebo 无效对照药
  • during 在的期间
  • controlled 受控
  • sclerosis 硬化